DDInter556 DDInter462
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
Dihydrocodeine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dihydrocodeine {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Dabrafenib
Dihydrocodeine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Dihydrocodeine {u} (Compound) causes {v} (Side Effect) Abdominal pain
Abdominal pain {u} (Side Effect) is caused by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dabrafenib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Dabrafenib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dihydrocodeine {u} (Compound) causes {v} (Side Effect) Mental disorder
Mental disorder {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dabrafenib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Oxymorphone {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Dabrafenib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dabrafenib
Dihydrocodeine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Dihydrocodeine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Dabrafenib
Dihydrocodeine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Dihydrocodeine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Dabrafenib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Dihydrocodeine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Dihydrocodeine (Compound) resembles Oxymorphone (Compound) and Oxymorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Dabrafenib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)